Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: A Multicenter National Cohort Study
{"title":"Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: A Multicenter National Cohort Study","authors":"Kohei Nakata, Yoshihiro Miyasaka, Takeaki Ishizawa, Masayuki Ohtsuka, Masamichi Mizuma, Sohei Satoi, Masaaki Hidaka, Shuji Suzuki, Hiroshi Kurahara, Chie Kitami, Satoshi Hirano, Dongha Lee, Saiho Ko, Munenori Tahara, Isaku Yoshioka, Kenjiro Date, Kazuyuki Nagai, Goro Honda, Shugo Mizuno, Kenichi Hakamada, Yasuro Futagawa, Shigeru Marubashi, Hiroshi Yoshida, Akihiko Horiguchi, Yasuo Hosouchi, Masafumi Imamura, Naoto Gotohda, Hiroaki Nagano, Masaji Tani, Takeshi Sudo, Teijiro Hirashita, Junichi Arita, Katsutoshi Murase, Ken Fukumitsu, Toshiki Rikiyama, Teruyuki Usuba, Toshiya Abe, Masafumi Nakamura, Itaru Endo","doi":"10.1002/jhbp.12181","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In this study, we investigated the criteria that predict the long-term survival benefits after surgical resection in patients with pancreatic cancer accompanied by liver oligometastasis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In total, 60 patients from 34 high-volume Japanese centers who underwent surgical resection for liver oligometastasis between 2005 and 2020 were included. Univariate and multivariate methods of survival analyses were performed. All patients were followed up for at least 36 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall survival (OS) was significantly longer in the preoperative chemotherapy group than in the up-front surgery group (37.4 vs. 20.4 months, <i>p</i> = 0.001). In the operation with preoperative chemotherapy group, a complete response was observed in eight patients (28.6%). The 1-, 3-, and 5-year OS rates were 92.9%, 50.0%, and 35.7%, respectively. The multivariate analysis showed that low CA19-9 (< 100 U/mL; HR: 0.25; 95% CI: 0.06–0.96; <i>p</i> = 0.043), low CEA (< 5 U/mL; HR: 0.14; 95% CI: 0.04–0.48; <i>p</i> = 0.002), and resectable (R) or borderline resectable pancreatic cancer invading the portal vein (BR-PV) status (HR: 0.19; 95% CI: 0.07–0.51; <i>p</i> < 0.001) were positive prognostic factors. The median OS of the patients who met all three criteria was 106.6 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Preoperative chemotherapy is essential for the treatment of liver oligometastases. Despite the high recurrence rates, patients who met the specific criteria have a favorable prognosis with liver resection.</p>\n </section>\n </div>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":"32 8","pages":"611-619"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jhbp.12181","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12181","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
In this study, we investigated the criteria that predict the long-term survival benefits after surgical resection in patients with pancreatic cancer accompanied by liver oligometastasis.
Methods
In total, 60 patients from 34 high-volume Japanese centers who underwent surgical resection for liver oligometastasis between 2005 and 2020 were included. Univariate and multivariate methods of survival analyses were performed. All patients were followed up for at least 36 months.
Results
Overall survival (OS) was significantly longer in the preoperative chemotherapy group than in the up-front surgery group (37.4 vs. 20.4 months, p = 0.001). In the operation with preoperative chemotherapy group, a complete response was observed in eight patients (28.6%). The 1-, 3-, and 5-year OS rates were 92.9%, 50.0%, and 35.7%, respectively. The multivariate analysis showed that low CA19-9 (< 100 U/mL; HR: 0.25; 95% CI: 0.06–0.96; p = 0.043), low CEA (< 5 U/mL; HR: 0.14; 95% CI: 0.04–0.48; p = 0.002), and resectable (R) or borderline resectable pancreatic cancer invading the portal vein (BR-PV) status (HR: 0.19; 95% CI: 0.07–0.51; p < 0.001) were positive prognostic factors. The median OS of the patients who met all three criteria was 106.6 months.
Conclusion
Preoperative chemotherapy is essential for the treatment of liver oligometastases. Despite the high recurrence rates, patients who met the specific criteria have a favorable prognosis with liver resection.
期刊介绍:
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.